PPP2CA Recombinant antibody

• 

  WB analysis using 84155-5-RR

  Various lysates were subjected to SDS PAGE followed by western blot with 84155-5-RR (PPP2CA antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.

• 

  Affinity and Kinetic Characterization of 84155-5-RR

  Biolayer interferometry (BLl) kinetic assays of 84155-5-RR against Human PPP2CA were performed. The affinity constant is 13.6 nM.

PPP2CA Recombinant Antibody for WB, ELISA

Cat No. 84155-5-RR

Clone No.241112B8

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, ELISA

Synonyms

PP2CA, PP2Ac, PP2A-alpha, PP2A alpha, EC:3.1.3.16

---

Tested Applications

• Positive WB detected in: MCF-7 cells, Jurkat cells

Recommended dilution

• Western Blot (WB): WB : 1:2000-1:10000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

84155-5-RR targets PPP2CA in WB, ELISA applications and shows reactivity with human samples.

• Tested Reactivity: human
• Host / Isotype: Rabbit / IgG
• Class: Recombinant
• Type: Antibody
• Immunogen: PPP2CA fusion protein Ag4294
• Full Name: protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform
• Calculated Molecular Weight: 309 aa, 36 kDa
• Observed Molecular Weight: 36 kDa
• GenBank Accession Number: BC031696
• Gene Symbol: PPP2CA
• Gene ID (NCBI): 5515
• RRID: AB_3671719
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Protein A purfication
• UNIPROT ID: P67775
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol , pH 7.3
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

PPP2CA, also named as RP-C and PP2A-alpha, belongs to the PPP phosphatase family and PP-1 subfamily. PP2A can modulate the activity of phosphorylase B kinase casein kinase 2, mitogen-stimulated S6 kinase, and MAP-2 kinase. PP2A activity was modestly decreased in AML patients harboring C-KIT/WT.PP2A is a target for C-KIT/TKD and implicated the potential efficacy of therapies targeting PP2A in such AML in future.